Full Press Release Details
For More Information:
Chief Financial Officer
Curis, Inc. Announces Appointment of Marc Rubin, M.D.
to its Board of Directors
CAMBRIDGE, MA, June 4, 2010 Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small
molecule drug candidates for cancer treatment, today announced the appointment of Marc Rubin, M.D. to its Board of Directors. Dr. Rubin brings extensive clinical development, medical, commercial and scientific expertise to Curis, having held
executive-level clinical development positions with Bayer Schering Pharma, Schering AG and GlaxoSmithKline.
We are very pleased to have
Dr. Rubin join our board. We expect that his addition will enhance the expertise of the board as it guides Curis forward in its effort to become a leading small molecule cancer drug development company, said Curis President and CEO Daniel
R. Passeri. We have made important advances over the past few years in progressing our pipeline of promising cancer programs, including completing Phase I dose escalation clinical testing of CUDC-101 and planning for future clinical testing of
this molecule, which is our proprietary first-in-class HDAC, EGFR, Her2 inhibitor for cancer network disruption. We have also advanced additional preclinical targeted small molecules that are designed to disrupt cancer networks. In addition, our
collaborators have continued to advance our partnered assets, including Genentech s testing of Hedgehog Pathway Inhibitor GDC-0449 in three Phase II clinical studies and Debiopharm s Phase I testing of Heat Shock Protein 90 inhibitor Debio
0932. We look forward to Dr. Rubin s contributions as we continue to move these programs forward and believe that his extensive experience with pharmaceutical development will prove highly valuable to Curis.
Dr. Rubin has served as Executive Chairman of the Board of Directors of Titan Pharmaceuticals, Inc. since May 2009. He held the position of
President and Chief Executive Officer of Titan Pharmaceuticals from October 2007 until December 2008. From June 2006 until February 2007, Dr. Rubin served as Head of Global Research and Development for Bayer Schering Pharma, as well as a member
of the Executive Committee of Bayer Healthcare and the Board of Management of Bayer Schering Pharma. Beginning in October 2003 and until
the merger of Bayer Pharmaceuticals and Schering AG in June 2006, Dr. Rubin was a member of the Executive Board of Schering AG with responsibility for global development and for three global
business units, including the oncology business unit, as well as Chairman of Schering Berlin Inc. and President of Berlex Pharmaceuticals, a division of Schering AG. From 1990 until August 2003, Dr. Rubin was employed by GlaxoSmithKline where
he held positions in global clinical and commercial development overseeing programs in the United States, Europe, Asia and Latin America. From 2001 through 2003, he was Senior Vice President of Global Clinical Pharmacology & Discovery
Prior to his pharmaceutical industry career, Dr. Rubin completed subspecialty training and board certification in both medical
oncology and infectious diseases at the National Cancer Institute within the National Institutes of Health (1983-1986). Dr. Rubin also served as an Investigator and on the Senior Staff of the infectious diseases section at the National Cancer
Institute from 1986 until 1989. Dr. Rubin holds an M.D. from Cornell University Medical College. In addition to his role of Executive Chairman of the Board of Directors of Titan Pharmaceuticals, Dr. Rubin currently serves on the board of
directors of Surface Logix, a biotechnology company, and the Rogosin Institute, a not-for-profit medical treatment and research institution. Dr. Rubin also served on the board of directors of Medarex, Inc. prior to its acquisition by
Bristol-Myers Squibb Co. in 2009.
I am enthusiastic about my appointment to Curis board of directors and look forward to working
with the other members of the board to oversee the continued advancement of what I believe is an impressive portfolio of targeted cancer drug candidates, said Dr. Rubin. In my role as a Curis director, I intend to leverage my drug
discovery, development and commercialization expertise to help Curis to continue its efforts to both advance its pipeline of targeted cancer drug candidates and, ultimately, to provide benefit to patients suffering from cancers that are not
effectively addressed with current therapies.
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted
small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs. For more information, visit
Curis website at www.curis.com.
Curis Cautionary Statement: This press release contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements with respect to the expected benefits of Dr. Rubin s addition to Curis board of director and the
Company s plans to advance its pipeline of therapeutic programs. Forward-looking statements used in this press release may contain the words believes ,
expects , anticipates , plans , seeks , estimates , will , may or similar expressions. These forward-looking
statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other important factors that may cause the actual results to be materially different from those indicated by such forward-looking statements
including, among other things:
In addition, any forward-looking statements
represent the views only as of today and should not be relied upon as representing Curis views as of any subsequent date. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press
release whether as a result of new information, future events or otherwise.